Soligenix Inc. (SNGX)
SNGX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$0.3348
-4.80% on the day
Market cap
$7.3M
Nano cap
Revenue · 2024
$119K
-85.8% on 2023
Net income · 2024
-$8.3M
-6953.1% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2024.
Profile
| Field | Value |
|---|---|
| Ticker | SNGX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0000812796 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2024
| Line | Value |
|---|---|
| Revenue | $119K |
| Net income | -$8.3M |
| Operating income | -$9.4M |
| Net margin | -6953.1% |
| Operating margin | -7907.7% |
| Revenue growth | -85.8% |
| Cash | Not in SEC XBRL data |
| Total assets | $9.0M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 61.0× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-08-07 |
| Latest annual report | 10-K | 2026-03-31 |
| Latest quarterly / interim | 10-Q | 2026-08-07 |
| Latest current report | 8-K | 2026-09-21 |
| Latest proxy | DEFA14A | 2026-08-03 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| INM | InMed Pharmaceuticals Inc. Common Shares | $1.33 | -2.21% | $7.3M |
| APUS | Apimeds Pharmaceuticals US Inc. | $4.62 | -11.15% | $7.1M |
| XCUR | Exicure Inc. | $1.15 | +5.50% | $7.5M |
| APRE | Aprea Therapeutics Inc. | $0.6000 | +1.16% | $7.6M |
| CALC | CalciMedica Inc. | $1.12 | -7.05% | $7.6M |
| CURX | Curanex Pharmaceuticals Inc | $4.88 | 0.00% | $7.7M |
| TCRT | Alaunos Therapeutics Inc. | $3.03 | +188.57% | $7.7M |
| LGVN | Longeveron Inc. | $2.15 | -12.24% | $6.9M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier